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1.0–1.9 (reference group), the hazard ratios (HRs) for primary 
outcome in the IDWG% <1.0, 2.0–2.9, 3.0–3.9, and  ≥ 4.0 
groups were 1.10 [95% confidence interval (CI) 0.55–2.20,
p = 0.80], 1.15 (95% CI 0.59–2.27, p = 0.68), 1.80 (95% CI 0.95–
3.41, p = 0.07), and 1.93 (95% CI 1.02–3.64, p = 0.04), respec-
tively. Furthermore, even when residual renal function and 
24-hour urine volume were adjusted, IDWG%  ≥ 4.0 remained 
as a significant predictor of primary outcome (HR 2.03, 95% 
CI 1.02–4.02, p = 0.04).  Conclusion: Increased IDWG% is a 
significant independent predictor of MACCE in incident HD 
patients. It could be helpful to prevent excessive IDWG for 
improving clinical outcomes in incident HD patients. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Interdialytic weight gain (IDWG), which corresponds 
to ultrafiltration losses during hemodialysis (HD), is the 
result of salt and water ingestion minus urine output be-
tween two consecutive dialysis sessions  [1, 2] . Previous 
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 Abstract 
 Background: Interdialytic weight gain (IDWG) has been re-
garded as a surrogate of volume overload, but also as a mark-
er of a better nutritional status in end-stage renal disease 
(ESRD) patients on hemodialysis (HD). This paradoxical 
meaning of IDWG requires further investigation, particularly 
in adverse cardiovascular outcomes.  Methods: A prospec-
tive cohort of 1,013 incident HD patients from 36 HD centers 
of the Clinical Research Center for ESRD in Korea was includ-
ed. Patients were categorized into five groups according to 
the IDWG%, a ratio of absolute IDWG to dry weight: <1.0, 
 ≥ 4.0, and every 1.0 increment in between. Primary outcome 
was major adverse cardiac and cerebrovascular events 
(MACCE).  Results: During a mean follow-up of 18.7 months, 
primary outcome was observed in 104 patients (10.3%). In 
multivariate analysis, compared to patients with IDWG% of 
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studies have revealed that excessive IDWG is associated 
with adverse clinical outcomes  [2–6] , finding it to be an 
independent predictor of all-cause and cardiovascular 
mortality in patients undergoing long-term HD  [2] . In ad-
dition, accumulating evidence shows that IDWG is sig-
nificantly associated with increases in blood pressure (BP) 
and left ventricular hypertrophy (LVH), both of which 
can increase the risk of cardiovascular mortality in pa-
tients with end-stage renal disease (ESRD)  [1, 7–12] . 
Moreover, IDWG was also considered one of several indi-
cators of non-adherence to dialysis therapy, a significant 
predictor of mortality and hospitalization in prevalent 
HD patients  [3, 4] . However, the impact of IDWG on clin-
ical outcomes is not straightforward  [13–20] . IDWG is 
proportional to the amount of food intake, as well as fluid 
and salt. In this regard, several studies have found a sig-
nificant positive correlation between IDWG and nutri-
tional markers, such as normalized protein catabolic rate 
(nPCR), serum albumin and creatinine, and body mass 
index (BMI)  [13–19] . Therefore, in some ways, IDWG is 
regarded as a marker of a better nutritional status, which 
is a favorable prognostic factor in ESRD patients  [16–19] .
 These conflicting results have led us to further verify 
the relationship between IDWG and clinical outcomes in 
patients starting HD. To date, most previous studies in-
vestigating the impact of IDWG on mortality and mor-
bidity were conducted in Western prevalent HD patients 
 [2, 3, 5, 6] , only Japanese prevalent HD patients were 
studied as a part of the Dialysis Outcomes and Practice 
Patterns Study (DOPPS)  [4] . Considering differences in 
culinary culture, nutritional status, and dialysis practice 
pattern, it has clinical relevance to investigate the prog-
nostic impact of IDWG in Asian incident HD patients. 
Furthermore, prior studies did not include residual renal 
function (RRF), 24-hour urine volume, and inflamma-
tory biomarkers in the final analysis, which are signifi-
cantly associated with IDWG and survival of HD patients 
 [2, 3, 5, 6, 18] . Therefore, in the present study, we clarified 
the prognostic value of IDWG in Korean incident HD 
patients from the Clinical Research Center for ESRD 
(CRC for ESRD) cohort, a nationwide prospective obser-
vational multicenter cohort in consideration of RRF, 24-
hour urine volume, and inflammation.
 Subjects and Methods 
 Study Design and Subjects 
 All ESRD patients who started HD between August 1, 2008 and 
December 31, 2012 in 36 centers of the CRC for ESRD in Korea were 
initially screened for this study. This study is a nationwide multi-
center joint network prospective cohort of ESRD patients in Korea 
designed to improve survival rates and quality of life and to create 
effective treatment guidelines (clinicaltrial.gov NCT00931970). Pa-
tients who were younger than 18 years, had histories of peritoneal 
dialysis or kidney transplantation before HD, had underlying active 
malignancy, or were expected to survive less than 3 months were 
excluded before the initial screening. Among 1,245 incident HD pa-
tients, those who died within 3 months of the commencement of 
HD, who did not receive three times weekly HD, or who had insuf-
ficient baseline demographic, laboratory, or IDWG data were also 
excluded from the study. Finally, a total of 1,013 incident HD pa-
tients were included in the final analysis.
 This study was carried out in accordance with the Declaration 
of Helsinki. The study protocol was approved by the institutional 
review board at each participating center, and all patients provided 
their written informed consent to participate in the study.
 Data Collection 
 Demographic and clinical data were collected at the time of 
study entry, and included age, gender, primary renal disease, co-
morbidities, type of vascular access, and medications. Coronary 
artery disease was defined as a history of angioplasty, coronary 
artery bypass grafts, myocardial infarction, or angina and cerebro-
vascular accident from a history of transient ischemic attack, 
stroke, or carotid endarterectomy; peripheral artery disease was 
defined as a history of claudication, ischemic limb loss and/or ul-
ceration, or any peripheral revascularization procedure. Predialy-
sis systolic and diastolic BP was recorded. BMI was calculated and 
subjective global assessment (SGA) was scored to access nutrition-
al status. Single pooled fractional urea clearance (Kt/V) urea and 
sodium concentrations of dialysate were obtained on the day of the 
midweek dialysis session, 3 months after HD initiation. RRF and 
urine volume were determined by a 24-hour urine collection. The 
following laboratory data were measured from predialysis fasting 
blood samples taken on the day of the midweek dialysis session 
close to the time of discharge, when the patients were considered 
to be clinically stable and in a euvolemic state, and every 3 months 
thereafter: hemoglobin, white blood cell, blood urea nitrogen 
(BUN), creatinine, calcium, phosphorus, intact parathyroid hor-
mone, glucose, uric acid, albumin, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, fer-
ritin, and plasma sodium concentrations. High-sensitivity C-reac-
tive protein (hs-CRP) levels were measured by a latex-enhanced 
immunonephelometric method using a BNII analyzer (Dade Beh-
ring, Newark, Del., USA). Echocardiography was performed on a 
non-dialysis day close to the time of discharge, based on the imag-
ing protocol recommended by the American Society of Echocar-
diography. Multiple reproducibility, inter-reader reliability, intra-
reader reliability, and reader drift analyses were performed at a 
core echocardiography laboratory (Kyungpook National Univer-
sity, Daegu, Korea) on a random sample of 3% of the entire cohort 
each year.
 Assessment of IDWG 
 Absolute IDWG was defined as the difference between predi-
alysis body weight of the midweek dialysis session and preceding 
postdialysis body weight, and the ratio of absolute IDWG to pa-
tient’s dry weight was defined as IDWG%. Dry weight was deter-
mined by the patients’ physicians (nephrologists) in the context of 
symptoms of intradialytic hypotension, BP, edema, or pulmonary 
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edema on chest X-ray. To mitigate intrapersonal variability, the 
mean value of three IDWG%2–4 months after HD initiation was 
used in the analysis.
 Outcome Measures 
 All deaths and hospitalization events were retrieved from the 
database of the CRC for ESRD and were carefully reviewed. Pri-
mary outcome was the incidence of major adverse cardiac and 
cerebrovascular events (MACCE), defined as death or hospitaliza-
tion from myocardial infarction, unstable angina, new onset or 
worsening of congestive heart failure, stroke, or arterial revascu-
larization.
 Statistical Analysis 
 Statistical analysis was performed using SPSS for Windows ver-
sion 18.0 (SPSS, Inc., Chicago, Ill., USA). Continuous variables 
were expressed as mean ± SD, or median (interquartile range), and 
categorical variables as a number (percentage). Normality of dis-
tribution was ascertained by the Kolmogorov-Smirnov test. Sub-
jects were categorized into five groups according to IDWG%: <1.0, 
 ≥ 4.0, and every 1.0 increment in between. To compare demo-
graphics, clinical characteristics, and laboratory findings among 
the groups, ANOVA with Bonferroni post hoc test or Kruskal-
Wallis test was used for continuous variables and the χ 2 test for 
categorical variables. Uni- and multivariate linear regression anal-
yses were performed to identify independent determinants of 
IDWG%. The independent prognostic value of IDWG% for pri-
mary outcome was ascertained by Cox proportional hazards re-
gression analysis, which included significant variables from the 
univariate analysis and variables associated with nutrition and in-
flammation in ESRD (BMI, SGA, and serum ferritin and hs-CRP 
concentrations). Since data of echocardiography and 24-hour 
urine study were available in 676 and 811 patients, respectively, 
additional models of linear regression analysis and Cox analysis 
were conducted for these patients. p values <0.05 were considered 
statistically significant.
 Results 
 Baseline Characteristics according to IDWG% 
Categories 
 The baseline demographics, clinical characteristics, 
and laboratory findings 3 months after HD commence-
ment according to IDWG% categories are shown in  tables 
1 and  2 . The mean age was 58.3 ± 14.2 (21–80) years, and 
609 patients (60.1%) were male. Diabetic nephropathy 
(53.8%) was the most common cause of ESRD, followed 
by hypertension (14.4%). At the initiation of HD, 138 
(13.6%) and 116 patients (11.4%) had coronary artery dis-
ease and congestive heart failure, respectively. The mean 
IDWG% of all patients was 2.8 ± 1.9%, and the mean 
IDWG% for each group was 0.4, 1.5, 2.5, 3.5, and 5.5%, 
respectively. There was a significant increased trend in 
the proportion of patients with diabetes, predialysis sys-
tolic BP at 3 months after HD initiation; serum glucose 
and phosphorus concentrations also increased with 
IDWG%, while residual urine volume, hemoglobin, se-
rum albumin and calcium, and plasma sodium levels 
tended to be significantly lower as IDWG% increased. 
There were no significant differences in comorbid dis-
eases, RRF, type of vascular access, dialysis adequacy, the 
use of medications, and echocardiographic parameters 
such as left atrial diameter (LAD), LV mass index (LVMI), 
and LV ejection fraction (LVEF).
 Association of IDWG% with Clinical and Biochemical 
Parameters 
 To identify independent variables associated with 
IDWG%, multivariate linear regression analysis was per-
formed ( table 3 ). Male gender, diabetes mellitus, predi-
alysis systolic BP, and serum phosphorus concentrations 
were positively correlated with IDWG%, while there were 
significant inverse relationships of IDWG% with BMI, se-
rum albumin and calcium, and plasma sodium levels. 
When RRF and 24-hour urine volumes were included in 
the regression model (model 2), 24-hour urine volume
(β = –0.14, p = 0.001) was revealed to be an independent 
predictor of IDWG%. Moreover, the associations of 
IDWG% with diabetes mellitus, predialysis systolic BP, 
BMI, serum albumin, and plasma sodium concentrations 
remained consistent.
 IDWG% as an Independent Risk Factor for MACCE 
 During a mean follow-up duration of 18.7 ± 11.7 
months, 32 patients (3.2%) died from cardiovascular 
causes, and primary outcome was observed in 104
patients (10.3%). The most often MACCE was myo-
cardial infarction (27 patients, 2.7%), followed by un-
stable and stable angina pectoris (16 patients, 1.6%, 
respec tively) (www.karger.com/doi/10.1159/000362743 
for online suppl. table 1). Cardiovascular death rates and 
the incidence rates of primary outcome were the highest 
in patients with IDWG%  ≥ 4.0 (2.88 and 9.77 per 100 pa-
tient-years, respectively). Univariate Cox proportional 
hazards analysis revealed that age [hazard ratio (HR) 
1.02, 95% confidence interval (CI) 1.01–1.04, p = 0.002], 
the presence of diabetes (HR 1.625, 95% CI 1.08–2.46,
p = 0.02) and previous cardiovascular disease (HR 2.50, 
95% CI 1.70–3.68, p < 0.001), log hs-CRP (HR 1.30, 95% 
CI 1.07–1.59, p = 0.01), and serum albumin levels (HR 
0.71, 95% CI 0.51–0.98, p = 0.04) were associated with an 
increased risk of primary outcome. In multivariate analy-
sis, compared to patients with IDWG% of 1.0–1.9 (refer-
ence group), the HRs of the IDWG% <1.0, 2.0–2.9, 3.0–
3.9, and  ≥ 4.0 groups were 1.10 (95% CI 0.55–2.20, p = 
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 Table 1.  Baseline demographics, clinical characteristics of subjects according to IDWG% categories
All <1.0% 1.0 – 1.9% 2.0 – 2.9% 3.0 – 3.9% ≥4.0% p
(n = 1,013) (n = 182) (n = 202) (n = 223) (n = 172) (n = 234)
IDWG, % of dry weight 2.8 ± 1.9 0.4 ± 0.3 1.5 ± 0.3 2.5 ± 0.3 3.5 ± 0.3 5.5 ± 1.4
Age, years 58.3 ± 14.2 58.6 ± 15.3 58.8 ± 14.3 57.9 ± 14.6 57.7 ± 13.0 58.4 ± 13.6 0.9
Male, n (%) 609 (60.1) 127 (69.8) 121 (59.9) 128 (57.4) 100 (58.1) 133 (56.8) 0.06
Primary renal disease, n (%) 0.02
Diabetic nephropathy 545 (53.8) 74 (40.6) 104 (51.5) 115 (51.6) 97 (56.4) 155 (66.2)
Hypertensive nephrosclerosis 146 (14.4) 32 (17.6) 31 (15.3) 39 (17.4) 24 (14.0) 20 (8.5)
Glomerulonephritis 129 (12.7) 29 (15.9) 27 (13.4) 29 (13.0) 22 (12.8) 22 (9.4)
Polycystic kidney disease 30 (3.0) 11 (6.0) 9 (4.5) 4 (1.8) 2 (1.2) 4 (1.7)
Othera 76 (7.5) 15 (8.2) 14 (6.9) 16 (7.2) 14 (8.1) 17 (7.3)
Unknown 87 (8.6) 21 (11.5) 17 (8.5) 20 (9.0) 13 (7.6) 16 (6.8)
Modified CCI 5.3 ± 2.5 5.1 ± 2.7 5.3 ± 2.4 5.1 ± 2.3 5.2 ± 2.2 5.6 ± 2.6 0.29
Comorbid disease, n (%)
Diabetes mellitus 578 (57.1) 78 (42.9) 109 (54.0) 123 (55.2) 110 (64.0) 158 (67.5) <0.001
Chronic lung disease 104 (10.3) 21 (11.6) 20 (9.9) 18 (8.1) 15 (8.7) 30 (12.8) 0.16
CAD 138 (13.6) 24 (13.2) 27 (13.4) 33 (14.8) 21 (12.2) 33 (14.1) 0.9
PAD 88 (8.7) 14 (7.7) 18 (8.9) 19 (8.5) 14 (8.1) 23 (9.8) 0.9
CVA 109 (10.8) 18 (9.9) 25 (12.4) 25 (11.2) 15 (8.7) 26 (11.1) 0.78
CHF 116 (11.4) 15 (8.2) 24 (11.9) 31 (13.9) 16 (9.3) 30 (12.8) 0.22
CVDb 322 (31.8) 55 (30.2) 65 (32.1) 73 (32.7) 49 (28.5) 80 (34.2) 0.76
Smoker, n (%) 438 (43.3) 88 (48.3) 82 (40.6) 89 (39.9) 77 (44.8) 102 (43.6) 0.09
Predialysis weight, kg 62.4 ± 11.0 63.2 ± 11.3 63.1 ± 11.6 62.1 ± 11.0 63.3 ± 10.3 61.0 ± 10.6 0.15
Postdialysis weight, kg 61.1 ± 10.8 63.1 ± 11.1 62.2 ± 11.1 60.8 ± 10.7 61.5 ± 10.1 58.6 ± 10.3 0.001
Predialysis SBP, mm Hg 144.2 ± 23.3 141.9 ± 24.5 144.8 ± 24.5 143.9 ± 21.4 145.3 ± 23.4 144.9 ± 23.1 0.63
Predialysis DBP, mm Hg 76.1 ± 14.5 76.0 ± 13.9 75.5 ± 14.6 76.2 ± 13.4 76.3 ± 15.0 76.6 ± 15.5 0.9
Vascular access, n (%) 0.31
AVF or AVG 295 (29.1) 47 (25.8) 66 (32.7) 76 (34.0) 48 (28.0) 58 (24.8)
Temporary catheter 682 (67.3) 125 (68.7) 126 (62.3) 142 (63.8) 120 (69.7) 169 (72.2)
Unknown 36 (3.6) 10 (5.5) 10 (5.0) 5 (2.2) 4 (2.3) 7 (3.0)
Medications, n (%)
RAS blockers 587 (57.9) 104 (57.1) 115 (56.9) 128 (57.4) 104 (60.5) 136 (58.1) 0.9
β-Blockers 523 (51.6) 81 (44.5) 107 (53.0) 124 (55.6) 99 (57.6) 112 (47.9) 0.18
Calcium channel blockers 579 (57.1) 90 (49.5) 118 (58.4) 135 (60.5) 100 (58.1) 136 (58.1) 0.40
Diuretics 529 (52.2) 78 (42.9) 110 (54.5) 121 (54.3) 102 (59.3) 118 (50.4) 0.08
Vitamin D 145 (14.3) 21 (11.5) 26 (12.9) 41 (18.4) 25 (14.5) 32 (13.7) 0.57
Calcium-based phosphate binder 493 (48.7) 90 (49.5) 99 (49.0) 108 (48.4) 87 (50.6) 109 (46.6) 0.21
Echocardiographic parametersc
LAD, cm 4.2 ± 0.7 4.1 ± 0.7 4.3 ± 0.7 4.3 ± 0.8 4.3 ± 0.6 4.3 ± 0.7 0.31
LVMI, g/m2 194.1 ± 82.3 191.6 ± 67.6 200.1 ± 78.6 195.8 ± 67.3 199.1 ± 82.3 202.7 ± 78.2 0.15
LVEF, % 58.6 ± 10.5 59.8 ± 10.4 59.3 ± 10.1 59.5 ± 10.1 58.3 ± 10.4 58.5 ± 11.4 0.36
 Data are expressed as the mean ± SD or number of patients (%). 
CAD = Coronary artery disease; PAD = peripheral artery disease; 
CVA = cerebrovascular accidents; CHF = congestive heart failure; 
CVD = cardiovascular disease; CCI = Charlson comorbidity index; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; 
AVF = arteriovenous fistula; AVG = arteriovenous graft; RAS = 
renin-angiotensin system.
a Interstitial nephritis, obstructive uropathy, and post status of 
nephrectomy. b A composite of CAD, PAD, CVA, and CHF.
c Echocardiographic parameters were available in 676 patients.
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 Table 2.  Clinical and laboratory parameters 3 months after HD commencement according to IDWG% categories
All <1.0% 1.0 – 1.9% 2.0 – 2.9% 3.0 – 3.9% ≥4.0% p
(n = 1,013) (n = 182) (n = 202) (n = 223) (n = 172) (n = 234)
Predialysis weight, kg 62.1 ± 11.0 61.8 ± 10.4 62.4 ± 11.5 61.7 ± 11.2 63.2 ± 10.9 61.5 ± 11.0 0.67
Postdialysis weight, kg 60.2 ± 10.7 61.0 ± 10.0 61.4 ± 11.3 60.1 ± 10.9 61.0 ± 10.5 58.3 ± 10.6 0.001
Predialysis SBP, mm Hg 144.2 ± 21.7 136.4 ± 19.7 143.4 ± 22.8 144.4 ± 21.3 145.3 ± 22.2 147.8 ± 21.0 0.001
Predialysis DBP, mm Hg 77.1 ± 13.1 74.7 ± 13.0 77.8 ± 12.6 77.0 ± 12.5 76.8 ± 13.4 78.6 ± 13.6 0.22
BMI 23.1 ± 3.4 23.3 ± 3.2 23.4 ± 3.7 23.2 ± 3.5 23.3 ± 3.4 22.7 ± 3.3 0.16
SGA 1.23 ± 0.61 1.26 ± 0.57 1.19 ± 0.63 1.18 ± 0.60 1.20 ± 0.58 1.30 ± 0.64 0.13
Kt/V urea 1.34 ± 0.37 1.30 ± 0.25 1.30 ± 0.36 1.33 ± 0.39 1.37 ± 0.44 1.38 ± 0.30 0.29
Dialysate Na, mEq/l 139.1 ± 1.9 139.0 ± 2.3 139.1 ± 1.6 139.1 ± 1.9 139.2 ± 1.7 139.1 ± 1.8 0.9
RRF, ml/min/1.73 m2 7.9 ± 4.2 8.4 ± 4.8 7.8 ± 3.9 7.7 ± 4.6 7.4 ± 3.6 7.9 ± 3.9 0.14
Urine volume, l/day 0.98 ± 0.55 1.14 ± 0.56 1.05 ± 0.54 0.95 ± 0.57 0.88 ± 0.47 0.91 ± 0.58 <0.001
Hemoglobin, g/dl 10.8 ± 1.5 11.0 ± 1.4 11.0 ± 1.3 10.7 ± 1.2 10.8 ± 1.3 10.6 ± 1.2 0.01
White blood cells, ×103/μl 7.2 ± 3.1 7.0 ± 2.9 7.1 ± 2.9 7.0 ± 3.3 7.2 ± 2.7 7.5 ± 3.3 0.33
Blood urea nitrogen, mg/dl 53.1 ± 21.5 51.9 ± 21.7 51.9 ± 18.5 53.5 ± 23.1 54.6 ± 22.3 54.5 ± 20.9 0.05
Creatinine, mg/dl 7.6 ± 3.0 7.4 ± 2.8 7.5 ± 2.9 7.5 ± 2.4 7.9 ± 3.7 7.8 ± 2.8 0.07
Albumin, g/dl 3.7 ± 0.5 3.8 ± 0.5 3.8 ± 0.5 3.7 ± 0.5 3.7 ± 0.5 3.6 ± 0.5 0.001
Glucose, mg/dl 143.4 ± 73.9 128.3 ± 65.7 140.2 ± 72.9 140.5 ± 62.6 152.4 ± 75.1 154.2 ± 87.0 <0.001
Uric acid, mg/dl 7.9 ± 2.8 8.0 ± 2.9  7.7 ± 2.6 7.9 ± 2.9 8.2 ± 2.7 7.7 ± 2.9 0.22
Total cholesterol, mg/dl 155.4 ± 38.9 157.9 ± 36.2 159.6 ± 40.6 156.8 ± 41.6 152.5 ± 36.7 150.3 ± 38.5 0.19
LDL cholesterol, mg/dl 83.3 ± 28.8 87.6 ± 28.3 85.3 ± 28.9 84.7 ± 30.2 81.4 ± 27.0 78.4 ± 29.4 0.11
HDL cholesterol, mg/dl 43.8 ± 15.2 43.5 ± 14.9 44.4 ± 15.9 44.1 ± 14.6 43.1 ± 14.6 43.9 ± 16.1 0.9
Calcium, mg/dl 7.8 ± 1.1 7.8 ± 1.2 7.9 ± 0.9 7.7 ± 1.1 7.6± 1.0 7.6 ± 1.0 <0.001
Phosphorus, mg/dl 5.4 ± 1.9 5.2 ± 1.9 5.2 ± 1.8 5.3 ± 1.7 5.8 ± 2.1 5.6 ± 2.0 0.009
iPTH, pg/ml 197 (109 – 324) 191 (104 – 317) 195 (106 – 316) 220 (119 – 369) 196 (127 – 320) 188 (99 – 299) 0.35
Ferritin, ng/ml 180 (127 – 356) 239 (138 – 390) 180 (105 – 279) 206 (113 – 366) 193 (119 – 394) 227 (129 – 391) 0.05
hs-CRP, mg/l 1.38 (1.21 – 1.57) 1.37 (1.01 – 1.74) 1.31 (0.91 – 1.72) 1.76 (1.29 – 2.22) 1.04 (0.69 – 1.39) 1.45 (1.03 – 1.87) 0.17
Na, mEq/l 137.0 ± 5.0 138.3 ± 4.1 137.3 ± 5.0 137.3 ± 4.3 136.5 ± 5.3 136.1 ± 5.6 0.001
 Data are expressed as mean ± SD or median (interquartile range). SBP = Systolic blood pressure; DBP = diastolic blood pressure; Na = sodium; LDL = 
low-density lipoprotein; HDL = high-density lipoprotein; iPTH = intact parathyroid hormone.
 Table 3.  Uni- and multivariate linear regression analysis of clinical and biochemical variables for increased IDWG%
Univariate Model 1a Model 2b
β (95% CI) p β (95% CI) p β (95% C I) p
Age (per 1 year increase) –0.01 (–0.01, 0.01) 0.84 –0.07 (–0.018, 0.001) 0.1 –0.08 (–0.019, 0.001) 0.08
Male (vs. female) 0.09 (0.13, 0.60) 0.003 0.10 (0.08, 0.61) 0.01 0.07 (–0.03, 0.54) 0.08
DM (vs. no) 0.14 (0.31, 0.78) <0.001 0.09 (0.06, 0.64) 0.03 0.12 (0.11, 0.76) 0.01
Predialysis SBPc (per 1 mm Hg increase) 0.12 (0.004, 0.016) 0.002 0.09 (0.002, 0.014) 0.01 0.09 (0.001, 0.014) 0.02
BMI (per 1 kg/m2 increase) –0.08 (–0.08, –0.01) <0.001 –0.09 (–0.09, –0.01) 0.01 –0.09 (–0.08, –0.01) 0.02
SGA (per 1 increase) 0.07 (0.02, 0.41) 0.03 0.04 (–0.11, 0.33) 0.34 0.06 (–0.07, 0.41) 0.16
Hb (per 1 g/dl increase) –0.11 (–0.25, –0.06) 0.001 –0.05 (–0.19, 0.04) 0.19 –0.08 (–0.23, 0.01) 0.07
Albumin (per 1 g/dl increase) –0.15 (–0.79, –0.29) <0.001 –0.07 (–0.64, –0.01) 0.04 –0.09 (–0.652, –0.002) 0.04
Glucose (per 1 mg/dl increase) 0.15 (0.002, 0.004) <0.001 0.06 (–0.001, 0.002) 0.22 0.07 (–0.001, 0.003) 0.13
Ca (per 1 mg/dl increase) –0.16 (–0.50, –0.20) <0.001 –0.12 (–0.42, –0.08) 0.004 –0.09 (–0.37, –0.01) 0.04
P (per 1 mg/dl increase) 0.11 (0.05, 0.23) 0.002 0.11 (0.04, 0.24) 0.005 0.09 (0.01, 0.22) 0.03
Na (per 1 mEq/l increase) –0.17 (–0.11, –0.05) <0.001 –0.07 (–0.053, –0.006) 0.01 –0.09 (–0.076, –0.002) 0.04
RRF (per 1 ml/min/1.73 m2 increase) –0.04 (–0.05, 0.01) 0.22 – – –0.08 (–0.074, 0.003) 0.07
UV (per 0.1 l/day increase) –0.15 (–0.74, –0.28) <0.001 – – –0.14 (–0.68, –0.19) 0.001
 DM = Diabetes mellitus; SBP = systolic blood pressure; Hb = hemoglobin; Ca = calcium; P = phosphorus; Na = sodium; UV = urine volume.
a Adjusted for sex, age, DM, predialysis SBP, BMI, SGA, Hb, albumin, glucose, Ca, P, and Na. b Model 1 + GFR and 24-hour UV. c Predialysis SBP was 
recorded 3 months after HD initiation.
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0.80), 1.15 (95% CI 0.59–2.27, p = 0.68), 1.80 (95% CI 
0.95–3.41, p = 0.07), and 1.93 (95% CI 1.02–3.64, p = 
0.04), respectively, after adjustment for demographic 
characteristics, nutritional status, and inflammatory bio-
chemical parameters ( table 4 , model 2). Furthermore, the 
predictive value of IDWG%  ≥ 4.0 for primary outcome 
remained significant after adjusting for each baseline 
echocardiographic parameter [model 2 ( table 4 ) + LAD, 
HR 1.91, 95% CI 1.03–3.53, p = 0.04; model 2 + LVMI, 
HR 1.89, 95% CI 1.02–3.50, p = 0.04; model 2 + LVEF, HR 
1.88, 95% CI 1.01–3.47, p = 0.04)].
 Prognostic Value of IDWG% in Subgroup Stratified by 
Residual Urine Volume 
 IDWG%  ≥ 4.0 was an independent predictor of MAC-
CE even after adjustment for RRF and 24-hour urine vol-
umes [model 2 ( table 4 ) + RRF and 24-hour urine volume, 
HR 2.03, 95% CI 1.02–4.02, p = 0.04]. In addition, when 
the patients were dichotomized by the median value of 24-
hour urine volume (0.9 l/day), the prognostic value of 
IDWG%  ≥ 4.0 for primary outcome was significant in the 
smaller urine output group (HR 1.95, 95% CI 1.01–3.02,
p = 0.04) after adjustment for various confounding factors, 
including nutritional and inflammatory biomarkers. The 
risk of IDWG%  ≥ 4.0 for primary outcome was also higher 
in the larger urine output group, but did not reach statisti-
cal significance (HR 1.32, 95% CI 0.57–3.04, p = 0.12).
 Discussion 
 IDWG has been considered a surrogate of volume 
overload in ESRD patients undergoing HD  [1–7, 12] , but 
it is also regarded as a marker of a better nutritional status 
 [13–19] . Even though a number of previous studies have 
investigated the prognostic value of IDWG in prevalent 
HD patients, the results have been inconsistent  [2–6, 16–
20] . In the current study, we demonstrate for the first time 
that excessive IDWG ( ≥ 4.0% of dry weight) is a signifi-
cant independent predictor of MACCE in incident ESRD 
patients starting HD, even after adjustment for the pres-
ence of diabetes and previous cardiovascular disease, 
malnutrition, inflammation, RRF, and 24-hour urine vol-
ume. Moreover, this study shows that IDWG has signifi-
cant inverse correlations with nutritional markers, but 
positive correlations with predialysis systolic BP. These 
findings suggest that prevention of excessive IDWG may 
be beneficial to clinical outcomes, even in incident HD 
patients, partly via protecting the heart from the deleteri-
ous effect of hypertension.
 IDWG is a weight gain between two consecutive dialy-
sis sessions, which is primarily dependent on the patient’s 
fluid and sodium intake  [1, 2] . To date, mounting evi-
dence indicates that a greater IDWG is associated with 
poor survival in ESRD patients on HD  [2–6] . In Swedish 
HD patients, the extent of IDWG was significantly great-
er in patients with cardiovascular outcomes compared to 
those without  [5] . Patients with IDWG  ≥ 5.7% of dry 
weight, one of the criteria used to define non-compliance, 
were also found to have a higher mortality risk  [3, 4] . 
Moreover, a large cohort study by Kalantar-Zadeh et al. 
 [2] revealed that the risks of all-cause and cardiovascular 
mortality were significantly higher in long-term HD pa-
tients with IDWG  ≥ 4.0 kg. Furthermore, a very recent 
study demonstrated that IDWG >3.0 kg was associated 
with a 1.29-fold increase in all-cause mortality, indepen-
dent of dialysis session length  [6] . However, most previ-
ous studies, which investigated the adverse effects of 
 Table 4.  Cox proportional hazard models of IDWG% categories for MACCE
Unadjusted Model 1a  Model 2b
HR (95% CI) p HR (95% CI) p H R (95% CI) p
<1.0 1.07 (0.54 – 2.11) 0.85 1.71 (0.80 – 2.46) 0.23 1.10 (0.55 – 2.20) 0.80
1.0 – 1.9 1 (reference) 1 (reference) 1 (reference)
2.0 – 2.9 1.17 (0.57 – 2.29) 0.65 1.13 (0.65 – 1.96) 0.66 1.15 (0.59 – 2.27) 0.68
3.0 – 3.9 1.63 (0.87 – 3.05) 0.13 1.73 (1.00 – 2.98) 0.05 1.80 (0.95 – 3.41) 0.07
≥4.0 2.07 (1.12 – 3.82) 0.02 1.74 (1.04 – 2.91) 0.04 1.93 (1.02 – 3.64) 0.04
 DM = Diabetes mellitus; SBP = systolic blood pressure; Ca = calcium; P = phosphorus; Na = sodium.
a Adjusted for sex, age, DM, previous history of cardiovascular disease, predialysis SBP 3 months after HD ini-
tiation. b Model 1 + BMI, SGA, and biochemical data (albumin, Ca, P, log ferritin, log hs-CRP, and plasma Na).
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IDWG on the clinical outcomes in ESRD patients on HD, 
were conducted in prevalent HD patients  [2, 3, 5, 6] , and 
presented limited data on Asian population  [4] . The dif-
ferences in culinary culture, body size, comorbid disease, 
dialysis environment, and clinical course of Asian dialysis 
patients warrant a study specifically investigating the 
prognostic impact of IDWG in Asian incident HD pa-
tients. In the present study, we demonstrate that excessive 
IDWG ( ≥ 4.0% of dry weight) is a significant predictor of 
poor cardiovascular outcome in a nationally representa-
tive cohort of Korean incident HD patients, an outcome 
consistent with the aforementioned studies  [2–6] .
 Meanwhile, some previous studies have indicated that 
a higher IDWG represents a better nutritional status, 
which led to favorable outcomes in ESRD patients  [16–
19] . IDWG had direct correlations with nPCR, serum al-
bumin, creatinine, and BUN concentrations, as well as 
BMI  [13–19] . Lopez-Gomez et al.  [18] found that the 
5-year mortality risk was significantly higher in patients 
with IDWG% of <3 compared to those with IDWG%  ≥ 3. 
Patients with higher IDWG% also had significantly high-
er nPCR, serum albumin, prealbumin, and phosphorus 
levels, all of which were closely correlated with amount of 
protein intake. They suggested that larger amounts of 
food and beverage intake resulted in a greater IDWG, and 
that the close association between IDWG and nutrition 
outweighed the negative effects of IDWG on fluid over-
load. However, other studies failed to demonstrate a sig-
nificant relationship between IDWG and serum albumin 
levels, which is the most commonly used indicator of nu-
tritional status  [21–23] . Chen et al.  [21] showed that new 
HD patients with higher IDWG had significantly lower 
BMI during the first year of therapy and that there was no 
significant difference in nutritional markers such as se-
rum albumin, phosphorus, creatinine, and BUN concen-
trations among patients with different IDWG%. The re-
sults of our study also did not find any significant positive 
correlations between nutritional parameters and IDWG%, 
which was in agreement with the results of the study by 
Chen et al.  [21] . The conflicting results regarding the as-
sociation of IDWG% and nutritional status in HD pa-
tients may be partly attributed to different study popula-
tions (prevalent vs. incident). Compared to prevalent HD 
patients, RRF and urine volume are relatively preserved 
in incident ESRD patients starting HD, and urine volume 
is certainly one of the principal determinants of IDWG in 
HD patients. The current study also revealed that 24-hour 
urine volume was the largest in patients with IDWG% 
<1.0 in spite of comparable RRF, and that residual urine 
volume was a significant independent predictor of 
IDWG%. In addition, when RRF and urine volume were 
included in multivariate analysis, the HR of excessive 
IDWG was further increased. Taken together, even 
though the precise measurement of food, salt, and water 
intake was not performed, we inferred that the patients 
with lower IDWG were those who had ability to compen-
sate fluid overload by larger residual urine volume rather 
than who had lesser appetite or poor oral intake. On the 
other hand, the impact of IDWG on the clinical outcome 
was further elucidated according to the amount of resid-
ual urine volume. The prognostic value of IDWG%  ≥ 4.0 
for primary outcome was significant in the smaller urine 
output group after adjustment for various confounding 
factors, including nutritional and inflammatory bio-
markers. Based on these results, we surmised that exces-
sive IDWG had a deleterious effect on the clinical out-
come, especially in incident HD patients with small re-
sidual urine volume.
 The mechanism by which IDWG affects cardiovascu-
lar morbidity and mortality can be speculated from the 
cardiovascular burden of volume overload, volume fluc-
tuation, and arterial hypertension. Since most HD pa-
tients are treated with dialysis on a three times weekly 
schedule, intermittent ultrafiltration can lead to fluctua-
tion in body fluid. These daily fluctuations in extracellu-
lar fluid volume might promote cardiac remodeling by 
the activation of mammalian target of rapamycin (mTOR) 
pathway  [24–29] , sympathetic nervous system, and re-
nin-angiotensin-aldosterone pathway  [30, 31] , resulting 
in LVH and cardiac fibrosis  [6] . In the present study, the 
baseline echocardiographic parameters were similar 
among the five IDWG% groups, and the independent 
prognostic value of IDWG%  ≥ 4.0 remained significant 
even after adjusting for each baseline echocardiographic 
parameter. Nevertheless, since echocardiography was 
performed once at the time of HD initiation, it was im-
possible to demonstrate the changes in echocardiograph-
ic parameters, which might imply the detrimental effect 
of volume fluctuation on cardiac remodeling, due to lack 
of follow-up echocardiography. A future study with 
short-term follow-up echocardiography is necessary to 
clarify whether volume fluctuation during the first 4 
months of HD treatment can worsen cardiac dysfunction 
in incident HD patients. Meanwhile, this study found that 
there was a significant increased trend in predialysis sys-
tolic BP 3 months after HD commencement as IDWG% 
increased. Since hypertension is closely associated with 
LVH in ESRD patients  [26, 27] , we inferred that hyper-
tension in patients with greater IDWG% might aggravate 
LVH, eventually leading to poor cardiovascular out-
D
ow
nl
oa
de
d 
by
: 
Yo
ns
ei
 U
ni
ve
rs
ity
12
8.
13
4.
20
7.
84
 - 
12
/1
1/
20
14
 8
:0
1:
37
 A
M
 Lee  /Doh  /Kim  /Koo  /Oh  /Park  /Han  /Yoo  /
Kim  /Kim  /Yang  /Kim  /Kang  
 
 Am J Nephrol 2014;39:427–435 
DOI: 10.1159/000362743
434
comes. Moreover, in a study of 125 HD patients, 24-hour 
ambulatory BP monitoring revealed that greater IDWG 
was associated with a linear increase in the slope of BP 
during interdialytic period and the circadian amplitude 
was blunted by increments in IDWG  [12] . Increased noc-
turnal BP and loss of normal circadian rhythm were 
known to be implicated in cardiovascular mortality in 
HD patients  [32, 33] . Based on these findings, arterial hy-
pertension might also contribute to poor clinical out-
comes in this study.
 Our study has several limitations. First, IDWG was not 
determined at every dialysis session. Furthermore, dry 
weight is variable during the early period after the initia-
tion of HD treatment  [34] . Therefore, the mean values of 
at least three IDWG% after 2–4 months of HD initiation 
were used in the current study. Nevertheless, it was dif-
ficult to examine whether the change in IDWG% during 
the study period exerted any influence on clinical out-
comes. Second, an objective assessment of dry weight by 
bioimpedence analyses, relative plasma volume monitor-
ing, or chest ultrasonography was not performed in this 
study, making it difficult to discriminate whether our 
subjects were in a volume-overloaded or depleted state at 
the end of the HD session. Third, since the study subjects 
were all Korean incident HD patients, the association be-
tween IDWG and the clinical outcome mortality may not 
be generalized to other populations. Fourth, the follow-
up duration was relatively short, making it difficult to re-
cruit a sufficient number of patients for a longitudinal 
study. Since this prospective observation cohort study is 
ongoing, the long-term association between IDWG% and 
cardiovascular events can be further elucidated in the fu-
ture. Lastly, primary outcome in the present study was 
relatively small compared to those in previous studies on 
Western ESRD patients. We hypothesize that the differ-
ence is mainly attributed to disparate ethnicities, since the 
mortality rates of our patients were comparable to those 
of Japanese patients on HD  [35] . Despite these limita-
tions, the current study investigated the association of 
IDWG with various nutritional and inflammatory pa-
rameters, and RRF. In addition, the independent prog-
nostic impact of IDWG on cardiovascular outcomes was 
revealed in a large and ethnically homogenous incident 
HD patient cohort.
 In conclusion, the results of our study demonstrate 
that excessive IDWG ( ≥ 4.0% of dry weight) is a signifi-
cant independent predictor of MACCE in incident HD 
patients. Furthermore, there was a significant correlation 
between IDWG and predialysis systolic BP. These find-
ings suggest that prevention of excessive IDWG may be 
beneficial to cardiovascular outcomes even in incident 
HD patients, partly via protecting the heart from the del-
eterious effect of hypertension.
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